Latest ebit for LYKALABS.NS: $-38M, below the Healthcare sector average of $1.1T.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
The latest EBIT for LYKALABS.NS is $-38M as of September 2026. That compares with $63M in the prior-year period — down 161.0% year over year. That is below the Healthcare sector average of $1.1T. Investors often review this figure alongside Lyka Labs Limited's historical trend and sector peers before judging valuation or financial health.
Over the past year, LYKALABS.NS's EBIT moved from $63M to $-38M — a 161.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lyka Labs Limited's operating scale or balance-sheet position.
Against Healthcare companies, LYKALABS.NS currently prints $-38M for EBIT, while the sector average sits near $1.1T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Lyka Labs Limited's growth, margins, and balance sheet.
A EBIT figure of $-38M for LYKALABS.NS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.1T. Explore the charts below for those layers of context.
After noting LYKALABS.NS's EBIT ($-38M), review year-over-year change from $63M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.